Profile picture of Henrik Zetterberg

Prof Henrik Zetterberg

Group Leader

Pioneering the development of fluid biomarkers for dementia

Biography

With a background in molecular biology and medicine, Prof Henrik Zetterberg has spent the past 15 years focusing on the development of biomarkers for Alzheimer’s disease and other brain disorders - becoming a world expert in the process. He has published more than 1100 scientific articles and has received numerous awards.

News

Key publications

Acta neuropathologica communications
Published

Cerebrospinal fluid and frontal cortex TMPRSS2 and ACE2 protein levels differ in Down syndrome and Alzheimer's disease

Authors
Carlos Avilés-Granados, Adriana Gea-González, Jorge Sáez-Leyva, Sylvia E Perez, Elliott J Mufson, Ann-Charlotte Granholm, María Carmona-Iragui, Henrik Zetterberg, Kaj Blennow, Juan Fortea, María-Salud García-Ayllón, Javier Sáez-Valero
Cerebrospinal fluid and frontal cortex TMPRSS2 and ACE2 protein levels differ in Down syndrome and Alzheimer's disease
Journal of neurology
Published

Cerebrospinal fluid alpha-internexin concentrations measured in patients with Guillain-Barré syndrome: a possible prognostic biomarker for disability at 12 months

Authors
Nina Gleisner, Francisco Meda, Magnus Johnsson, Igal Rosenstein, Ellen Alpsten, Lenka Novakova, Jan Lycke, Henrik Zetterberg, Hlin Kvartsberg, Brynhildur Hafsteinsdottir, Markus Axelsson
Cerebrospinal fluid alpha-internexin concentrations measured in patients with Guillain-Barré syndrome: a possible prognostic biomarker for disability at 12 months
Alzheimer's research & therapy
Published

Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer's disease

Authors
Valentina Di Caro, Eunah Cho, Jill Thiel, Britney N Lizama, Marleen J A Koel-Simmelink, Kiran Pandey, Duc Duong, Nicholas T Seyfried, Michael Grundman, Charlotte E Teunissen, Henrik Zetterberg, Kaj Blennow, Anthony O Caggiano, Mary E Hamby
Impact of zervimesine on the neuroinflammatory biomarker GFAP and related proteomic molecular correlates in plasma of participants from a phase 2 clinical trial in Alzheimer's disease

Zetterberg Lab

Explore the work of the Zetterberg Lab, pioneering the development of fluid biomarkers for dementia

Zetterberg Lab